VolitionRX Ltd
VNRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.26M
Close$
$1.02
19.7% downside
Current Fair Value
19.7% downsideOvervalued by 19.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.26 Million |
|---|---|
| Enterprise Value | $10.26 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.4 |
| Beta | 1.12 |
| Outstanding Shares | 6,882,744 |
Return
| Return on Equity | 124.28% |
|---|---|
| Return on Assets | -272.21% |
| Return on Invested Capital | -212.04% |
Valuation & Multiples
| P/E Ratio | -0.32 |
|---|---|
| PEG | -1.39 |
| Price to Sales | - |
| Price to Book Ratio | -0.42 |
| Enterprise Value to Revenue | 4.16 |
| Enterprise Value to EBIT | 1.07 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | -0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 21, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
$753,575
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-0.70
Average shareholder expectationRevenue Estimate
$442,006
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 20.94%▲ 6.03% |
|---|---|
| Total Invested | $4.52M▲ 9.50% |
| Investors Holding | 31▲ 3.00% |
ESG Score
No data
About VolitionRX Ltd
65 employeesVolition is a multi-national epigenetics company developing simple, easy to use, costeffective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients...